Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy
Key facts
- Who runs it
- Exoneural Network AB
- Where
- Germany2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 34 people enrolled
- Started
- 17 Apr 2023
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Exopulse Mollii Suit
- Sham Exopulse Mollii Suit
- Record updated
- 5 August 2026
Who can take part
- Age
- 5 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients will be included if they
- are between 5 and 12 years of age
- have a clinical diagnosis of unilateraal or bilateral spastic CP by birth [15]
- have a PBS score between a minimum of 15 and a maxmimum of 44 points
- are able to walk freely, with slight limitation or using ancillary equipment's (GMFCS score ≤3) [49]
- are German speakers, able to understand verbal instructions
- have spasticity with a score of at least 1+ on the MAS
Who cannot take part
- have a change in their pharmacological therapy over the last three months or are planning to do so during the study
- have received botulinum toxin (botox) therapy in the last 3 months before the start of the study
- have a cardiac stimulator, a ventriculoperitoneal shunt, intrathecal baclofen pump
- suffer from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain)
- Patients will not be included if they
- are included in another research protocol during the study period
- are unable to undergo clinical procedures for the study purposes due to geographical or social reasons
- have a body mass index above 35 kg/m2,
- have contraindications to wearing Exopulse Mollii Suit, receive a medical device other than Exopulse Mollii during the study period
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cerebral Palsy (CP) is is estimated to be around 1.5-3 per live birth, with prenatal factors accounting for 75% of cases. CP appears in early childhood and persists with age and is characterized by permanent lesions or abnormalities affecting the immature brain. It mainly occurs as a motor system disorder (e.g., abnormal movements or posture) with the presence of hemiplegia, diplegia or tetraplegia, and spastic, dyskinetic or atactic syndromes. .This study will explore the potential clinical benefits of the Molliimethod in children with cerebral palsy. Spasticity impacts balance and mobility, halts the patients quality of life and their ability to perform their activity of daily living, and could also increase the risk of fractures and falls. Available interventions that aim on improving spasticity are facing limitations such as varios side effects. Therefore, developing novel therapies such as the EXOPULSE Mollii Suit could help to overcome such limitations and noninvasively improve balance, mobility, quality of life and reduce spasticity and pain in children with CP.
The 2 groups in the trial
- Active StimulationExisting treatment, for comparison
Active sessions will last 1 hour of stimulation per day for 2 weeks. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
Treatment: Exopulse Mollii Suit
- Sham StimulationSham treatment, for comparison
In the sham condition, subjects will be asked to wear the device for 1 hour per day for 2 weeks. During 1 hour use per day, the actual stimulation will last only 1 minute and then will shut off.
Treatment: Sham Exopulse Mollii Suit
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects of EXOPULSE Mollii Suit on Motor Functions in Children With Cerebral Palsy (EXOCEP 2 GER)
- Record updated
- 5 August 2026